China National Biotec Group (CNBG) said on Tuesday its experimental coronavirus vaccine has triggered antibodies in clinical trials and the company plans late-stage human trials in foreign countries.
Developed by a Wuhan-based research institute affiliated to CNBG’s parent company Sinopharm, the vaccine was found to have induced high-level antibodies in all inoculated people without serious adverse reaction, according to the preliminary data from a clinical trial initiated in April involving 1,120 healthy participants aged between 18 and 59.
CNBG said it is proactively seeking opportunities for late-stage and large-scale Phase 3 trials overseas.
“[We] have secured cooperative intent with companies and institutes in many countries,” the company said in a statement.
State media reported that the vaccine candidate, along with a different experimental shot developed by Sinopharm’s unit, has been offered to Chinese employees at state-owned firms travelling overseas as developers seek more data on their efficacy.